The PROGRESS trial three years later: time for more action, less distraction
暂无分享,去创建一个
[1] R. Wennberg,et al. The PROGRESS trial three years later: time for a balanced report of effectiveness , 2004, BMJ : British Medical Journal.
[2] M. Duerden. Secondary prevention for stroke and transient ischaemic attacks , 2004, BMJ : British Medical Journal.
[3] S. Priori,et al. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.
[4] F. Turnbull. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.
[5] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[6] M. Woodward,et al. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. , 2003, European heart journal.
[7] B. Psaty,et al. The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study. , 2002, American journal of hypertension.
[8] M. Woodward,et al. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .
[9] J. Slattery,et al. Blood pressure and risk of stroke in patients with cerebrovascular disease , 1996, BMJ.